Latest Lonza News & Updates
See the latest news and media coverage for Lonza. We track all announcements, press releases, and industry mentions in real time, all in one place.
Dedicated CDMO serving the healthcare industry
lonza.com- Headquarters
- Basel, Switzerland
- Founded year
- 1897
- Company type
- Public company
- Number of employees
- 15,000+
Last updated
Latest news about Lonza
In short: Lonza reported strong 2025 growth with CHF 6.5 billion in sales, initiated a $3 billion divestment of its CHI unit, and accelerated its CDMO strategy.
Company announcements
-
Lonza delivers strong Q1 2026 performance
Confirms full-year outlook with 11-12% sales growth and EBITDA margin above 32%. Completes transformation to pure-play CDMO via CHI divestment.
-
Lonza announces 2026 AGM results
All board motions approved. Jean-Marc Huët re-elected as Chair. New board members elected. CHF 5.00 dividend approved, up 25%.
-
Lonza licenses SYNtecan technology to Bristol Myers Squibb
Agreement grants BMS exclusive access to SYNtecan linker-payload platform for an undisclosed ADC target. Lonza eligible for upfront, milestone, and royalty payments.
-
Lonza achieves 2030 GHG intensity target early
Lonza generates 50% more value with same GHG footprint since 2018, updates target to 2021 base year, and reaches 100% renewable electricity in US, Europe, China by 2026.
Media coverage
-
Lonza announces results of the 2026 Annual General Meeting - All proposals of the Board of Directors were approved
Lonza Group AG / Keyword(s): Annual General Meeting Lonza announces results of the 2026 Annual General Meeting - All proposals of...
-
Lonza: Q1 Performance In Line With Expectations; Confirms 2026 Outlook
(RTTNews) - Lonza (LONN.SW) reported a strong first quarter performance across its CDMO business in line with the expected trajectory for full...
-
Lonza Stock News: Lonza in the afternoon loss rich
The Lonza stock belongs on Thursday afternoon to the losers of the day. The Lonza stock was last quoted in red in SIX SX trading and lost 1.0 percent...
-
Lonza cuts DNA-to-IND timelines to 13 months
Lonza has introduced an integrated drug development model that reduces timelines for certain bispecific antibodies from 22-24 months to just 13 months. The approach applies...
Track Lonza and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Lonza competitors & trending companies
Browse news for competitors to Lonza and other trending companies.
Recipharm
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove